These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 567088)

  • 1. Where is L-DOPA decarboxylated in the striatum after 6-hydroxydopamine nigrotomy?
    Duvoisin RC; Mytilineou C
    Brain Res; 1978 Aug; 152(2):369-73. PubMed ID: 567088
    [No Abstract]   [Full Text] [Related]  

  • 2. Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries.
    Melamed E; Hefti F; Wurtman RJ
    Brain Res; 1980 Sep; 198(1):244-8. PubMed ID: 7407592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changed eating and locomotor behaviour in the rat after 6-hydroxydopamine lesions to the substantia nigra.
    Brook C; Iversen SD
    Neuropharmacology; 1975 Feb; 14(2):95-105. PubMed ID: 1171387
    [No Abstract]   [Full Text] [Related]  

  • 4. [Different effects on dopamine receptors D1 and D2 following long-term usage of L-dopa].
    Wei D
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Apr; 24(2):104-7, 125. PubMed ID: 1830547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
    Melamed E; Hefti F; Bitton V; Globus M
    Neurology; 1984 Dec; 34(12):1566-70. PubMed ID: 6504328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density.
    Masuo Y; Pélaprat D; Montagne MN; Scherman D; Rostène W
    Brain Res; 1990 Mar; 510(2):203-10. PubMed ID: 1970504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
    Huang L; Deng M; He Y; Lu S; Ma R; Fang Y
    Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):634-43. PubMed ID: 26991136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD; Creese I
    Adv Neurol; 1975; 9():81-92. PubMed ID: 1170717
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine agonist potencies of ergolines.
    Lew JY; Nakamura S; Battista AF; Goldstein M
    Commun Psychopharmacol; 1979; 3(3):179-83. PubMed ID: 115634
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative evaluation of the blood-brain barrier capacity to form dopamine from circulating L-DOPA.
    Hardebo JE; Edvinsson L; Owman C; Rosengren E
    Acta Physiol Scand; 1977 Mar; 99(3):377-84. PubMed ID: 848309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats.
    Geula C; Slevin JT
    Synapse; 1989; 4(3):248-53. PubMed ID: 2532792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of nigrostriatal 6-hydroxydopamine lesions on dopamine D2 receptor mRNA and opioid systems.
    Mansour A; Meador-Woodruff JH; Camp DM; Robinson TE; Bunzow J; Van Tol H; Civelli O; Akil H; Watson SJ
    Prog Clin Biol Res; 1990; 328():227-30. PubMed ID: 2106148
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine antagonist binding increases in two behaviorally distinct striatal denervation syndromes.
    Thal L; Mishra RK; Gardner EL; Horowitz SG; Varmuza S; Makman MH
    Brain Res; 1979 Jul; 170(2):381-6. PubMed ID: 572733
    [No Abstract]   [Full Text] [Related]  

  • 16. L-dopa activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra.
    Robertson GS; Herrera DG; Dragunow M; Robertson HA
    Eur J Pharmacol; 1989 Jan; 159(1):99-100. PubMed ID: 2495972
    [No Abstract]   [Full Text] [Related]  

  • 17. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
    Brannan T; Knott P; Kaufmann H; Yahr M
    Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
    [No Abstract]   [Full Text] [Related]  

  • 19. Circling behavior in normoxic or hypoxic rats with unilateral 6-OHDA nigrostriatal lesion. Part 1. Effects of apomorphine and L-dopa.
    Saligaut C; Daoust M; Moore N; Boismare F
    Methods Find Exp Clin Pharmacol; 1987 Apr; 9(4):219-24. PubMed ID: 3110513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic grafts in the striatum reduce D1 but not D2 receptor-mediated rotation in 6-OHDA-lesioned rats.
    Robertson GS; Fine A; Robertson HA
    Brain Res; 1991 Jan; 539(2):304-11. PubMed ID: 1675908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.